加载中
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
前收盘价
US$4.90
−US$0.04 · -0.81%
盘前
US$4.83
−US$0.07 · -1.43%
10月13日 4:34 ET
盘中时间采用ET。市场数据可能有所延迟。
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
日内区间
当前US$4.90
52周区间
当前US$4.90
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
51
合理估值
情绪
41
多空交织
风险
45
风险偏高
动量
75
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
日内区间
当前US$4.90
52周区间
当前US$4.90
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.67
上涨空间 260.61%价格历史记录不可用
最高：US$21.00平均的：US$17.67最低：US$15.00| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2000年3月31日 | US$0.593Irregular | — | — |
除息 2000年3月31日
US$0.593
Irregular
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI894.48万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM593.65万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF367.24万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO147.29万0.01%180亿 USD0.06%US$112.27-0.35%
Simplify Propel Opportunities ETFSURI135.4万1.79%7606.44万 USD2.82%US$17.2565+0.23%
iShares Micro-Cap ETFIWC71.29万0.05%13.17亿 USD0.60%US$181.66-0.73%
iShares Core S&P Total U.S. Stock Market ETFITOT59.4万0.00%980.88亿 USD0.03%US$169.43-0.14%
WisdomTree U.S. SmallCap FundEES46.04万0.07%6.81亿 USD0.38%US$65.46-0.05%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTWisdomTree U.S. SmallCap FundEESAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
